Previous studies have demonstrated that several molecular markers, such as IDH mutations, chromosome 1p/19q co-deletions, etc., can be used for glioma diagnosis, treatment planning and prognosis assessment (Eckel-Passow et al., 2020). This evidence concerns the gene IDH1 and central nervous system cancer.